KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Capital Expenditures (2016 - 2025)

NovoCure (NVCR) has disclosed Capital Expenditures for 12 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 45.25% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.6 million through Dec 2025, down 37.82% year-over-year, with the annual reading at $26.6 million for FY2025, 37.82% down from the prior year.
  • Capital Expenditures hit $4.9 million in Q4 2025 for NovoCure, down from $5.7 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $14.3 million in Q4 2021 to a low of $2.6 million in Q2 2021.
  • Historically, Capital Expenditures has averaged $7.1 million across 5 years, with a median of $6.3 million in 2022.
  • Biggest five-year swings in Capital Expenditures: soared 147.86% in 2021 and later plummeted 54.95% in 2022.
  • Year by year, Capital Expenditures stood at $14.3 million in 2021, then tumbled by 54.95% to $6.4 million in 2022, then rose by 6.06% to $6.8 million in 2023, then surged by 31.1% to $8.9 million in 2024, then crashed by 45.25% to $4.9 million in 2025.
  • Business Quant data shows Capital Expenditures for NVCR at $4.9 million in Q4 2025, $5.7 million in Q3 2025, and $5.5 million in Q2 2025.